Sera Prognostics (NASDAQ:SERA), a biotech firm based in the United States, focuses on improving maternal and neonatal health through innovative blood tests. The company's primary project, the PreTRM test, aims to predict the risk of preterm birth, enabling earlier interventions and potentially better outcomes for mothers and babies. Sera Prognostics is committed to expanding its research and product line to address a wide range of pregnancy-related complications, striving to become a key player in prenatal care by leveraging cutting-edge technology and scientific findings.